Please assess the completion status of the following clinical trial:

Trial Title: The CRISIS Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~During the initial accrual period for this study, prior to the first interim analysis, patients will be eligible for enrollment if they:~* are between 12 months and less than 18 years; AND~* are within the first 48 hours of the PICU admission; AND~* have an endotracheal tube, central venous catheter (new or old, tunneled or not tunneled), or Foley catheter; AND~* are anticipated to have an indwelling arterial or central venous catheter for blood sampling during the first three days of study enrollment.~After the Data Safety Monitoring Board (DSMB) conducts its first interim evaluation, after enrollment of approximately 200 subjects, a decision will be made by the DSMB concerning enrollment of subjects between 40 weeks gestational age and 12 months. If the DSMB approves enrollment of infants after the first interim analysis, then patients will be eligible for enrollment if they:~* are between 40 weeks gestational age and less than 18 years; AND~* are within the first 48 hours of the PICU admission; AND~* have an endotracheal tube, central venous catheter (new or old, tunneled or not tunneled), or Foley catheter; AND~* are anticipated to have an indwelling arterial or central venous catheter for blood sampling during the first three days of study enrollment.~Exclusion Criteria:~During the initial accrual period for this study, prior to the first interim analysis, patients will be ineligible for enrollment if ANY of the following is true or anticipated:~* are less than 1 year age; OR~* are greater than or equal to 18 years of age; OR~* have a known allergy to metoclopramide; OR~* planned removal of endotracheal tube, central venous catheter, AND Foley catheters, within 72 hours of study enrollment, OR~* suspected intestinal obstruction, OR~* intestinal surgery or bowel disruption, OR~* chronic metoclopramide therapy prior to enrollment, OR~* failure to enroll within 48 hours of PICU admission, OR~* readmission to PICU in the previous 28 days, OR~* previously enrolled in this study, OR~* lack of commitment to aggressive intensive care therapies.~After the Data Safety Monitoring Board (DSMB) conducts its first interim evaluation, after enrollment of approximately 200 subjects, a decision will be made by the DSMB concerning enrollment of subjects between 40 weeks gestational age and 12 months. If the DSMB approves enrollment of infants after the first interim analysis, then patients will be ineligible for enrollment if ANY of the following is true or anticipated:~* are less than 40 weeks gestational age; OR~* are greater than or equal to 18 years of age; OR~* have a known allergy to metoclopramide; OR~* planned removal of endotracheal tube, central venous catheter, AND Foley catheters, within 72 hours of study enrollment, OR~* suspected intestinal obstruction

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- zinc selenium glutamine metoclopramide (Type: EXPERIMENTAL): metoclopramide, zinc, selenium, and glutamine
- enteral whey protein and IV saline (Type: PLACEBO_COMPARATOR): saline, sterile water, whey protein

Based on this trial design, predict the completion outcome and termination type (if applicable).